Company Description
Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally.
The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.
Its proprietary product candidates comprise Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; KYNMOBI, a sublingual film formulation of apomorphine for the treatment of episodic off-periods in Parkinson's disease; and Exservan, an oral soluble film formulation of riluzole for the treatment of amyotrophic lateral sclerosis.
The company's proprietary pipeline of complex molecule product includes AQST-108, a sublingual film formulation delivering systemic epinephrine for the treatment of conditions other than anaphylaxis; and Anaphylm, an epinephrine sublingual film for the emergency treatment of allergic reactions, including anaphylaxis.
In addition, it develops Adrenaverse, an epinephrine prodrug platform. The company was incorporated in 2004 and is headquartered in Warren, New Jersey.
| Country | United States |
| Founded | 2004 |
| IPO Date | Jul 25, 2018 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 135 |
| CEO | Daniel Barber |
Contact Details
Address: 30 Technology Drive Warren, New Jersey 07059 United States | |
| Phone | 908-941-1900 |
| Website | aquestive.com |
Stock Details
| Ticker Symbol | AQST |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001398733 |
| CUSIP Number | 03843E104 |
| ISIN Number | US03843E1047 |
| Employer ID | 20-8623253 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Daniel Barber | Chief Executive Officer, President and Director |
| Alexander Mark Schobel | Chief Innovation and Technology Officer |
| Lori J. Braender BSBA, Esq., J.D. | Senior Vice President, General Counsel, Chief Compliance Officer and Corporate Secretary |
| A. Ernest Toth Jr. | Chief Financial Officer |
| Cassie Jung | Senior Vice President of Operations |
| Peter E. Boyd | Senior Vice President of IT, Human Resources and Communications |
| Dr. Gary H. Slatko M.D., MBA | Chief Medical Officer |
| Dr. Stephen Wargacki | Senior Vice President of Research and Development |
| Dr. Carl N. Kraus M.D. | Chief Medical Officer |
| Robert Charles Arnold | Vice President of Finance, Controller and Assistant Secretary |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 24, 2024 | 424B2 | Prospectus |
| Apr 24, 2024 | 424B2 | Prospectus |
| Apr 23, 2024 | EFFECT | Notice of Effectiveness |
| Apr 22, 2024 | 8-K | Current Report |
| Apr 3, 2024 | S-3 | Registration statement under Securities Act of 1933 |
| Apr 1, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Apr 1, 2024 | 8-K | Current Report |
| Mar 21, 2024 | 8-K | Current Report |
| Mar 21, 2024 | 424B5 | Filing |
| Mar 19, 2024 | 424B5 | Filing |